Use of carotenoid derivatives to reduce the toxicity and increase the efficacy of anti-EGFR antitumor treatments
AssigneeAssociazione Oncologica Milanese Amo La Vita Onlus
InventorsMauro Moroni, Paolo Pedrazzoli, Marco Giulio Giuseppe Pirovano
Life of this patent
Estimating the term…
Abstract
The present invention refers to compounds of the carotenoid class, such as lycopene or lacto-lycopene, for their use in the treatment and/or prevention of toxicity caused by antitumor drugs, as well as their use in the treatment or remission of tumors in combination with antitumor drugs. Finally, the present invention refers to the combination of the above set forth compounds and drugs with antitumor action.
Claims5
A method of relieving, improving, decreasing and/or treating cutaneous and/or mucosal toxicity induced by at least one anti EGFR drug in patients in need thereof, said method comprising administering to said patients a combination consisting of a compound selected from lycopene and/or lacto-lycopene, or mixtures thereof, and at least one anti EGRF drug causing mucosal and/or cutaneous toxicity.
An antitumor therapy comprising administering to patients in need thereof a combination consisting of at least one anti EGRF drug and a compound selected from lycopene and/or lacto-lycopene, or mixtures thereof wherein said lycopene and/or lacto-lycopene or mixtures thereof relieve, improve, decrease and/or treat cutaneous and/or mucosal toxicity induced by said anti EGFR drug.
Dependencies are inferred from the claim text.